+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030

  • ID: 5447130
  • Report
  • September 2021
  • Region: Global
  • 126 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Blueprint Medicines
  • Bristol Myers Squibb
  • Camurus AB
  • Exelixis Inc
  • Hutchmed
  • Ipsen Pharma
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Neuroendocrine neoplasms are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body. Well-differentiated neuroendocrine tumors (NETs), represent the majority of NENs, and poorly differentiated neuroendocrine carcinomas (NECs), representing only 10─20% of all NENs. 62─67% of NETs occur in the gastrointestinal (GI) tract, specifically in the small intestine, appendix, and large intestine. 22─27% of NETs occur in the lungs, the second most common location of NETs, with about 30% of lung NETs occurring in the bronchial system, so-called bronchopulmonary. Approximately 7% of NETs can develop in the pancreas and 3% in the thymus.

The market of neuroendocrine cancers is facing some unique dynamics beginning in 2021. The class of somatostatin analogs is so important in the treatment of NETs that it represents approximately 55% of the global market share. In total, ~80% of this market’s value is under threat of generic competition. For this market to see true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products. With only five products in late-stage development, this is not the case and thus the market value is forecast to increase from $3.1B in 2020 to $3.4B in 2030, at a CAGR of 0.9% in the 8MM.

Key Highlights


  • The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to expansions of currently marketed therapies in new markets during the forecast period.
  • The main barriers to growth in the 8MM are patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care.
  • Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.
  • The most important unmet needs in the ALL market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.

KEY QUESTIONS ANSWERED

  • Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How has the introduction of Lutathera shaped the 2nd and 3rd lines of therapy? How will the competition fare?
  • What is the expected future uptake of immune checkpoint inhibitors across the 8MM?

Scope


  • Overview of Neuroendocrine Tumors including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Neuroendocrine Tumors market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Neuroendocrine Tumor therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
  • Analysis of the current and future market competition in the global Neuroendocrine Tumor therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy


The report will enable you to:


  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumor therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine Tumor market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Neuroendocrine Tumor therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Blueprint Medicines
  • Bristol Myers Squibb
  • Camurus AB
  • Exelixis Inc
  • Hutchmed
  • Ipsen Pharma
1. Neuroendocrine Tumors: Executive Summary
1.1 The Neuroendocrine Tumor Market Will Grow at a 0.9% CAGR During 2020-2030
1.2 Key Improvements in Existing Mechanisms of Action Form the Dominant Corporate and R&D Strategy in Neuroendocrine Tumors
1.3 Matching a Patient with the Most Appropriate Therapy Remains the Most Important Unmet Need in Neuroendocrine Tumors
1.4 Low Level of Innovation Across the Late-Stage Pipeline to Introduce Minimal Disruption in the Treatment Landscape
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods: Population - 8MM
4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs - 8MM
4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Type
4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Stage and Type
4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Grade and Differentiation
4.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of NETs
4.5 Epidemiological Forecast for NETs, 2020-2030
4.5.1 Diagnosed Incident Cases of NETs
4.5.2 Age-Specific Diagnosed Incident Cases of NETs
4.5.3 Sex-Specific Diagnosed Incident Cases of NETs
4.5.4 Diagnosed Incident Cases of NETs by Type
4.5.5 Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis
4.5.6 Diagnosed Incident Cases of NETs by Grade and Differentiation
4.5.7 Five-Year Diagnosed Prevalent Cases of NETs
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis

5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
5.2.1 Diagnosis
5.2.2 Surgical management
5.2.3 Systemic therapy

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Predictive Biomarkers to Match a Patient with the Most Appropriate Therapy
7.3 Safer Targeted Therapies for Low-Grade Tumors and More Efficacious Therapies for High-Grade Tumors
7.4 More Informed Use of Currently Available Drugs
7.5 Well-Tolerated Agents for SSTR Negative Tumors

8 R&D Strategies
8.1 Overview
8.1.1 Enhancing the Validated Strategy of PRRT
8.1.2 Novel Ways to Target SSTRs
8.1.3 Replacing Older Targeted Therapies with Next Generation Kinase Inhibitors and Immune Checkpoint Inhibitors
8.2 Clinical Trials Design
8.2.1 Endpoints More Suitable to NETs
8.2.2 Academically Sponsored and Collaborative Trials
8.2.3 Clinical Trial Challenges

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook

13 Appendix

List of Tables
Table 1: Neuroendocrine tumors: Key Metrics in the 8MM
Table 2: Grade and Proliferation Segmentation in Neuroendocrine Tumors
Table 3: Risk Factors and Comorbidities for NETs
Table 4: Treatment Guidelines for NETs
Table 5: Top 10 Deals by Value, 2011-2020
Table 6: NET Market - Global Drivers and Barriers, 2020-2030
Table 7: Key Events Impacting Sales for NETs in the US, 2020-2030
Table 8: NET Market - Drivers and Barriers in the US, 2020-2030
Table 9: Key Events Impacting Sales for NETs in the 5EU, 2020-2030
Table 10: NET Market - Drivers and Barriers in the 5EU, 2020-2030
Table 11: Key Events Impacting Sales for NETs in Japan, 2020-2030
Table 12: NET Market - Drivers and Barriers in Japan, 2020-2030
Table 13: Key Events Impacting Sales for NETs in China, 2020-2030
Table 14: NET Market - Drivers and Barriers in China, 2020-2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for NETs in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in NETs During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to Be Licensed for the Treatment of NETs During the Forecast Period
Figure 4: Key Therapeutic Targets in Neuroendocrine Tumors
Figure 5: 8MM, Diagnosed Incidence of NETs, Men, Cases per 100,000 Population, All Ages, 2010 and 2020
Figure 6: 8MM, Diagnosed Incidence of NETs, Women, Cases per 100,000 Population, All Ages, 2010 and 2020
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NETs
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Type
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Stage at Diagnosis, by Type
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Grade and Differentiation, by Type
Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NETs
Figure 12: 8MM, Diagnosed Incident Cases of NETs, N, Both Sexes, All Ages, 2020
Figure 13: 8MM, Diagnosed Incident Cases of NETs by Age, N, Both Sexes, 2020
Figure 14: 8MM, Diagnosed Incident Cases of NETs by Sex, N, All Ages, 2020
Figure 15: 8MM, Diagnosed Incident Cases of NETs by Type, N, Both Sexes, 2020
Figure 16: 8MM, Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis, N, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Incident Cases of NETs by Grade and Differentiation, N, Both Sexes, All Ages, 2020
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of NETs, N, Both Sexes, All Ages, 2020
Figure 19: Treatment Algorithm for NETs
Figure 20: Unmet Needs and Opportunities in Neuroendocrine Tumors
Figure 21: Overview of the Development Pipeline in NETs
Figure 22: Key Late-Stage Trials for the Promising Pipeline Agents that the Publisher Expects to Be Licensed for NETs in the 8MM During the Forecast Period
Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Afinitor and Lutathera
Figure 24: Analysis of the Company Portfolio Gap in NETs During the Forecast Period
Figure 25: Global (8MM) Sales Forecast by Country for NETs in 2020 and 2030
Figure 26: Sales Forecast by Class for NETs in the US in 2020 and 2030
Figure 27: Sales Forecast by Class for NETs in the 5EU in 2020 and 2030
Figure 28: Sales Forecast by Class for NETs in Japan in 2020 and 2030
Figure 29: Sales Forecast by Class for Neuroendocrine tumors in China in 2020 and 2030
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Blueprint Medicines
  • Bristol Myers Squibb
  • Camurus AB
  • Exelixis Inc
  • Hutchmed
  • Ipsen Pharma
  • ITM Isotopen Technologien Munchen
  • Merck & Co
  • Novartis
  • Pfizer
  • Progenics Pharmaceuticals
  • Roche
  • Shanghai Junshi Bioscience
Note: Product cover images may vary from those shown